United Therapeutics Corporation (NASDAQ:UTHR) Receives $505.00 Average Target Price from Analysts

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $505.00.

Several analysts recently weighed in on the stock. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Oppenheimer upped their price target on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Royal Bank Of Canada lifted their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $517.13 on Monday. The company has a 50 day simple moving average of $463.63 and a 200 day simple moving average of $380.56. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $518.61. The firm has a market cap of $22.27 billion, a PE ratio of 19.60, a price-to-earnings-growth ratio of 5.03 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.39 EPS. As a group, research analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 910 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $500.59, for a total transaction of $455,536.90. Following the completion of the sale, the director directly owned 8,480 shares in the company, valued at approximately $4,245,003.20. This trade represents a 9.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 2,000 shares of United Therapeutics stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $507.07, for a total value of $1,014,140.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $65,919.10. This trade represents a 93.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 625,164 shares of company stock valued at $284,916,107 over the last 90 days. 10.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently added to or reduced their stakes in the business. AIA Group Ltd bought a new stake in United Therapeutics in the third quarter worth approximately $545,000. Allworth Financial LP grew its position in shares of United Therapeutics by 26.1% during the 3rd quarter. Allworth Financial LP now owns 449 shares of the biotechnology company’s stock worth $188,000 after buying an additional 93 shares during the period. Cambria Investment Management L.P. increased its stake in shares of United Therapeutics by 20.9% in the 3rd quarter. Cambria Investment Management L.P. now owns 2,657 shares of the biotechnology company’s stock valued at $1,114,000 after acquiring an additional 460 shares in the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of United Therapeutics by 66.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company’s stock valued at $299,000 after acquiring an additional 284 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of United Therapeutics in the 3rd quarter valued at $644,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.